Recombinant Human ALDH1A3 Protein (N-6His)

Beta LifeScience SKU/CAT #: BL-1634NP
BL-1634NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
BL-1634NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Recombinant Human ALDH1A3 Protein (N-6His)

Beta LifeScience SKU/CAT #: BL-1634NP
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description Recombinant Human Aldehyde Dehydrogenase Family 1 Member A3 is produced by our E.coli expression system and the target gene encoding Met1-Pro512 is expressed with a 6His tag at the N-terminus.
Accession P47895
Synonym Aldehyde dehydrogenase family 1 member A3; ALDH1A3; Aldehyde dehydrogenase 6; Retinaldehyde dehydrogenase 3; RALDH-3; ALDH6
Gene Background Aldehyde dehydrogenase 1 family member A3 (ALDH1A3), also known as retinaldehyde dehydrogenase 3 (RALDH3), is a member of the aldehyde dehydrogenase family known to metabolize a wide variety of aldehydes. ALDH1A3 specifically oxidizes retinal to retinoic acid (RA) and is differentially expressed in developing embryonic tissues and adult organs. The RA produced by ALDH1A3 in rodents contributes to the development of skin and hair follicles, brain, tooth buds, lungs, olfactory bulbs, kidneys, eyes, skeletal muscle and seminal vesicles. In recent research, ALDH1A3 could be as a marker of cancer stem cell to predict metastasis or clinical prognosis in many cancers.
Molecular Mass 57.5 KDa
Apmol Mass 55-60 KDa, reducing conditions
Formulation Supplied as a 0.2 μm filtered solution of 20mM Tris-HCl, 150mM NaCl, 20% Glycerol, pH 7.5.
Endotoxin Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity Not tested
Reconstitution
Storage Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Shipping The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below.
Usage For Research Use Only

Target Details

Target Function NAD-dependent aldehyde dehydrogenase that catalyzes the formation of retinoic acid. Has high activity with all-trans retinal, and has much lower in vitro activity with acetaldehyde. Required for the biosynthesis of normal levels of retinoic acid in the embryonic ocular and nasal regions; retinoic acid is required for normal embryonic development of the eye and the nasal region.
Subcellular Location Cytoplasm.
Protein Families Aldehyde dehydrogenase family
Database References
Associated Diseases Microphthalmia, isolated, 8 (MCOP8)
Tissue Specificity Expressed at low levels in many tissues and at higher levels in salivary gland, stomach, and kidney.

Gene Functions References

  1. We also detected increased aldehyde dehydrogenase (ALDH) activity associated with overexpression of specific ALDH isoform 1A3. Its inhibition by siRNA approach partially sensitized cells to various agents, thus linking for the first time the ALDH1A3 and chemoresistance in colorectal cancer. PMID: 30143021
  2. Data indicate that aldehyde dehydrogenase 1A3 (ALDH1A3), that is directly involved in therapy resistance of glioblastoma, is regulated by autophagy during chemotherapy. PMID: 29306018
  3. ALDH1A3 suppression could be one of PPARG tumor suppressive function. This study provides a better understanding of the role of PPARG in lung cancer. PMID: 29873276
  4. Here the authors report the first crystal structure of human ALDH1A3 complexed with NAD(+) and the product all-trans retinoic acid (REA). The tetrameric ALDH1A3 folds into a three domain-based architecture highly conserved along the ALDHs family. The structural analysis revealed two different and coupled conformations for NAD(+) and REA that the authors propose to represent two snapshots along the catalytic cycle. PMID: 27759097
  5. Data show that retinoic acid receptor responder 1 (RARRES1) expression is subtype-dependent and regulated by DNA methylation and the expression of aldehyde dehydrogenase 1A3 (ALDH1A3). PMID: 27286452
  6. ALDH1A3 is a poor prognostic factor for patients with intrahepatic cholangiocarcinoma who underwent hepatectomy and in those with advanced intrahepatic cholangiocarcinoma receiving chemotherapy. PMID: 27076629
  7. high transcription activities of ALDH1A2, ALDH1A3 and ALDH1L1 predicted worsen overall survival in gastric cancer patients PMID: 27015121
  8. Melanoma treatment with the novel irreversible isoform-specific ALDH1 inhibitor [4-dimethylamino-4-methyl-pent-2-ynthioic acid-S methylester] di-methyl-ampal-thio-ester (DIMATE) or depletion of ALDH1A1 and/or ALDH1A3, promoted the accumulation of apoptogenic aldehydes leading to apoptosis and tumor growth inhibition in immunocompetent, immunosuppressed and patient-derived xenograft mouse models. PMID: 28581514
  9. these findings ascribe a novel function for ALDH1A3 in an aggressive glioma stem cells phenotype via the up-regulation of tissue transglutaminase PMID: 28423611
  10. our findings define a FOXD1-ALDH1A3 pathway in controling the clonogenic and tumorigenic potential of mesenchymal glioma stem-like cells in glioblastoma tumors PMID: 27569208
  11. we looked up our single center primary prostate cancer post-operative follow-up data and suggested that the high level ALDH1A3 expression could predict the poor progression-free survival in a 158-patient cohort. We concluded that ALDH1A3, localized in luminal layer in prostate epithelium, is highly expressed in prostate cancer PMID: 28443495
  12. this report brings new information for the phenotype-genotype correlation of ALDH1A3 mutations and raises important questions, especially in terms of genetic counselling given to the patients and their families PMID: 26873617
  13. ALDH1A3 was most relevant to extracellular matrix organization and cell adhesion biological process, and the ability of tumor invasion was suppressed after ALDH1A3 knockdown in vitro. PMID: 26575197
  14. the prevalence of ALDH1A3(+)/CD44(+) tumor cells in breast cancer is significantly associated with worse prognostic factors and favors a poor prognosis PMID: 26687806
  15. Whole-exome sequencing in a South American cohort links ALDH1A3, FOXN1 and RARB/retinoic acid regulation pathways to autism spectrum disorders. PMID: 26352270
  16. we demonstrated that a specific ALDH isoform, namely ALDH1A3, is enriched in chemoresistant mesothelioma cell subpopulations PMID: 25868979
  17. ALDH1A3 induces differential RA signaling in breast cancer cells which affects the rate of breast cancer progression. PMID: 25106087
  18. ALDH1A3 is a target of miR-187 in human prostate cancer. PMID: 25969992
  19. Increased hypermethylation of ALDH1A3 is associated with Glioblastoma. PMID: 25684492
  20. Among unique genes up-regulated by Y15 in Lovo-1 and K1 resistant cells, a stem cell marker-ALDH1A3-was detected to be up-regulated >twofold. PMID: 25656374
  21. High ALDH1A3 expression is associated with non-small cell lung cancer. PMID: 24907115
  22. Mutations in ALDH1A3 represent a frequent cause of microphthalmia/anophthalmia in consanguineous families. PMID: 24777706
  23. At the transcript level, the cisplatin + DEAB-resistant cells showed upregulated mRNA expression levels for ALDH1A2, ALDH1A3 isozymes and CD44 indicating the involvement of these markers in conferring chemoresistance PMID: 24884875
  24. Nine individuals, from one inbred kindred, segregating isolated A/M with orbital cysts were homozygous for a missense mutation in the gene encoding the A3 isoform of the ALDH1A3. PMID: 23881059
  25. Novel ALDH1A3 mutations identified in the present study confirm the pivotal role of ALDH1A3 in human eye development. PMID: 24568872
  26. ALDH1A3 may be upregulated in pancreatic cancer PMID: 24053169
  27. ALDH1A3 expression determines the stem cell-like cellular states in EGFR-mutant non-small cell lung cancer; a novel mechanism of acquired resistance to erlotinib can be targeted with the natural polyphenol silibinin. PMID: 24047698
  28. Our data support the very recent and independent identification of ALDH1A3 as a disease gene in microphthalmia. PMID: 23646827
  29. Results show that ALDH1A3 loss of function causes anophthalmia and aberrant eye development in humans and in animal model systems. PMID: 23591992
  30. The effects of phenotypic and morphological alterations by DEAB on oral keratinocytes are mainly consequent to the inhibition of ALDH1A3 activity. PMID: 23250514
  31. The methylation status of Homeobox A9 (HOXA9), ISL LIM homeobox 1 (ISL1) and Aldehyde dehydrogenase 1 family, member A3 (ALDH1A3) was significantly associated with decreased gene expression levels PMID: 23436614
  32. two subtypes of GSCs, harboring distinct metabolic signaling pathways, represent intertumoral glioma heterogeneity and highlight previously unidentified roles of ALDH1A3-associated signaling that promotes aberrant proliferation of Mes HGGs and GSCs. PMID: 23650391
  33. Homozygosity for one splice-site and two missense mutations in the gene encoding the A3 isoform of the aldehyde dehydrogenase 1 (ALDH1A3) in three consanguineous families, is reported. PMID: 23312594
  34. ALDH1A3 transcripts are detected at high levels in luminal progenitor-enriched fractions obtained from short-term adherent cultures of freshly isolated normal human mammary cells. PMID: 22131125
  35. ALDH1A3 expression in patient breast tumors correlates significantly with tumor grade, metastasis, and cancer stage PMID: 21280157
  36. these results indicate that the regulation of the retinoic acid metabolism in the epidermis involves transcriptional activation of ALDH1A3, possibly representing a positive feedback loop, which enhances the effect of exogenous retinoic acid. PMID: 20709019
  37. play a major role in the detoxification of aldehydes generated by alcohol metabolism and lipid peroxidation. PMID: 7698756

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed